Soligenix Inc. Highlighted for Innovation in Rare Disease Treatment

Soligenix Inc. (NASDAQ: SNGX) has been featured in a NetworkNewsWire editorial titled 'Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators,' highlighting the company's HyBryte(TM) platform as a significant advancement in the treatment of cutaneous T-cell lymphoma (CTCL), a rare skin cancer predominantly affecting older adults. The editorial sheds light on the increasing healthcare challenges posed by rare diseases in the aging American population and the critical need for effective therapies.

The HyBryte(TM) platform represents a novel photodynamic therapy utilizing safe visible light, with its active ingredient now being manufactured in the U.S., showcasing Soligenix's dedication to domestic innovation and support for underserved patient populations. This development is particularly noteworthy as it underscores the potential for long-term revenue generation through the commercialization of innovative treatments for rare diseases, a sector that has historically been overlooked due to the small patient populations involved.

For more information on Soligenix's advancements in rare disease treatment, visit https://ibn.fm/4UuJW. The company's commitment to addressing unmet medical needs through its Specialized BioTherapeutics and Public Health Solutions business segments is a testament to the importance of continued investment and innovation in the biopharmaceutical industry.